Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) Institutional Ownership

13F Institutional Holders and Ownership History from Q1 2021 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.0001 per share
Symbol
CGEM on Nasdaq
Shares outstanding
59,244,054
Price per share
$11.92
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
63,181,833
Total reported value
$653,781,665
% of total 13F portfolios
0%
Share change
+1,991,521
Value change
+$34,241,925
Number of holders
150
Price from insider filings
$11.92
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Lynx1 Capital Management LP 14% +100% $50,697,778 +$24,599,905 8,549,084 +94% Lynx1 Capital Management LP 08 Oct 2025
BIOTECHNOLOGY VALUE FUND L P 10% $64,748,182 5,918,481 BVF PARTNERS L P/IL 31 Dec 2025
VANGUARD GROUP INC 5.6% +12% $34,139,516 +$3,676,103 3,298,504 +12% The Vanguard Group 31 Dec 2025
Flynn James E 5% $17,357,187 2,927,013 Deerfield Mgmt, L.P. 30 Sep 2025
FRANKLIN RESOURCES INC 3.8% $17,836,873 2,191,262 Franklin Resources, Inc. 30 Sep 2024
CITADEL ADVISORS LLC 3.4% -34% $11,794,219 -$6,049,899 1,988,907 -34% Kenneth Griffin 30 Sep 2025

As of 31 Dec 2025, 150 institutional investors reported holding 63,181,833 shares of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM). This represents 107% of the company’s total 59,244,054 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) together control 91% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Lynx1 Capital Management LP 15% 8,963,500 +55% 19% $92,772,225
MPM BIOIMPACT LLC 13% 7,648,268 0% 9.1% $79,159,574
BVF INC/IL 9.7% 5,750,683 0% 2% $59,519,569
BlackRock, Inc. 7.4% 4,400,296 +5.5% 0% $45,543,064
VANGUARD GROUP INC 5.6% 3,298,504 +12% 0% $34,139,516
Kynam Capital Management, LP 5.3% 3,114,132 +35% 2.1% $32,231,266
Blue Owl Capital Holdings LP 4% 2,350,972 -6.4% 7.5% $24,332,560
STATE STREET CORP 3.7% 2,197,338 +31% 0% $22,742,448
Affinity Asset Advisors, LLC 3.3% 1,932,106 +632% 1.4% $19,997,297
RTW INVESTMENTS, LP 2.9% 1,705,960 0% 0.18% $17,656,686
VR ADVISER, LLC 2.3% 1,379,965 0% 0.71% $14,282,638
GEODE CAPITAL MANAGEMENT, LLC 2.2% 1,302,262 +0.54% 0% $13,481,334
BOOTHBAY FUND MANAGEMENT, LLC 2.1% 1,237,043 0.34% $12,803,395
Siren, L.L.C. 2% 1,193,410 0% 0.37% $12,351,794
Nextech Invest, Ltd. 1.9% 1,141,145 0% 1.1% $11,810,851
DIMENSIONAL FUND ADVISORS LP 1.4% 848,769 -28% 0% $8,783,184
MORGAN STANLEY 1.3% 766,934 +92% 0% $7,937,772
GOLDMAN SACHS GROUP INC 1.2% 721,864 -27% 0% $7,471,292
GREAT POINT PARTNERS LLC 1.1% 634,032 2.1% $6,562,231
RENAISSANCE TECHNOLOGIES LLC 1.1% 631,706 +19% 0.01% $6,538,157
TWIN FOCUS CAPITAL PARTNERS, LLC 1% 595,489 0% 0.71% $6,163,311
DEUTSCHE BANK AG\ 0.99% 586,636 +2.6% 0% $6,071,683
Nuveen, LLC 0.98% 579,095 +169% 0% $5,993,634
TWO SIGMA INVESTMENTS, LP 0.79% 470,526 +689% 0.01% $4,869,944
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.74% 436,273 +8.4% 0% $4,515,426

Institutional Holders of Cullinan Therapeutics, Inc. - Common Stock, par value $0.0001 per share (CGEM) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 63,181,833 $653,781,665 +$34,241,925 $10.35 150
2025 Q3 61,075,479 $362,176,403 -$12,503,420 $5.93 142
2025 Q2 62,610,123 $471,432,056 -$15,598,491 $7.53 141
2025 Q1 64,669,430 $489,559,204 -$25,799,469 $7.57 145
2024 Q4 65,580,571 $798,774,691 -$43,310,126 $12.18 144
2024 Q3 65,000,732 $1,087,002,831 -$1,185,148 $16.74 136
2024 Q2 62,920,773 $1,097,340,923 +$411,767,308 $17.44 134
2024 Q1 39,359,979 $670,698,022 +$49,224,262 $17.04 113
2023 Q4 36,858,851 $375,589,972 +$26,958,804 $10.19 110
2023 Q3 38,010,712 $344,003,620 +$11,040,871 $9.05 104
2023 Q2 36,693,312 $394,818,289 +$48,696,476 $10.76 102
2023 Q1 32,209,329 $329,495,842 -$56,320,751 $10.23 97
2022 Q4 37,711,425 $397,852,399 +$5,318,094 $10.55 94
2022 Q3 37,032,227 $474,756,845 -$7,043,826 $12.82 94
2022 Q2 37,570,810 $481,656,895 +$20,400,666 $12.82 81
2022 Q1 36,763,865 $384,914,646 +$4,824,538 $10.47 77
2021 Q4 36,386,962 $559,714,828 +$6,266,769 $15.43 74
2021 Q3 33,862,280 $762,265,836 +$33,803,888 $22.57 63
2021 Q2 32,250,659 $828,539,736 -$17,650,444 $25.75 70
2021 Q1 31,323,171 $1,298,948,827 +$1,298,948,827 $41.67 70